CVS Health (CVS) Stock
Key stats
- Market cap
- $114.54B
- Price / Earnings ratio
- 10.3x
- EPS (TTM)
- $8.67
- Volume
- Loading
- 52-week high
- $110.68
- 52-week low
- $69.51
- Dividend yield
- 2.97%
- Dividend amount (latest)
- $0.67
- EPS vs analyst estimate
- +17.6%Q3 FY25 · $1.60 vs $1.36
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with CVS
Recent news

CVS breaking up its healthcare empire — splitting pharmacies from insurance business
CVS breaking up its healthcare empire — splitting pharmacies from insurance business
CVS

CVS Stock Rises After Hours On Alleged Pharmacy Spin-Off Ahead Of Q3 Earnings Report
CVS Stock Rises After Hours On Alleged Pharmacy Spin-Off Ahead Of Q3 Earnings Report
CVS

‘Too Cheap to Ignore'? What to Watch When CVS and McDonald's Report
‘Too Cheap to Ignore'? What to Watch When CVS and McDonald's Report
CVS

Mark Cuban Says Public Companies Found They Were ‘Ripped Off’ On Healthcare But Won’t Say So On Earnings Calls
Mark Cuban Says Public Companies Found They Were ‘Ripped Off’ On Healthcare But Won’t Say So On Earnings Calls
CVS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.38
- MACD 12/26/9
- -1.09
- EMA 9 of MACD
- -0.94
- MACD histogram
- -0.16
- SMA 50
- $89.97
- Price below SMA 50
- EMA 50
- $90.28
- Price below EMA 50
- SMA 200
- $89.02
- Price above SMA 200
- EMA 200
- $87.65
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.77 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

CVS breaking up its healthcare empire — splitting pharmacies from insurance business
CVS breaking up its healthcare empire — splitting pharmacies from insurance business
CVS

CVS Stock Rises After Hours On Alleged Pharmacy Spin-Off Ahead Of Q3 Earnings Report
CVS Stock Rises After Hours On Alleged Pharmacy Spin-Off Ahead Of Q3 Earnings Report
CVS

‘Too Cheap to Ignore'? What to Watch When CVS and McDonald's Report
‘Too Cheap to Ignore'? What to Watch When CVS and McDonald's Report
CVS

Mark Cuban Says Public Companies Found They Were ‘Ripped Off’ On Healthcare But Won’t Say So On Earnings Calls
Mark Cuban Says Public Companies Found They Were ‘Ripped Off’ On Healthcare But Won’t Say So On Earnings Calls
CVS

Countdown to CVS Health (CVS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Countdown to CVS Health (CVS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
CVS

Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
CVS

CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
CVS

CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS
CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS
CVS

Should You Buy CVS Health Stock While It's Under $100?
Should You Buy CVS Health Stock While It's Under $100?
CVS

CVS Health Q3 Earnings Preview: How to Approach the Stock?
CVS Health Q3 Earnings Preview: How to Approach the Stock?
CVS
News tone: automated (AI) classification of the article's content, not a price prediction.
About CVS Health
We are a health care innovation company with a simple and clear purpose: Helping people on their path to better health. We’re united around a common goal of becoming the most consumer-centric health company.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. J. David Joyner CEBS | CEO, President & Chairman | 1965 |
| Mr. Brian O. Newman | Executive VP & CFO | 1969 |
| Mr. Tilak Mandadi | EVP of Ventures and Chief Experience & Technology Officer | 1964 |
| Mr. Prem S. Shah Pharm.D | Executive VP & Group President | 1980 |
| Mr. Steven Hale Nelson M.B.A. | Executive VP & President of Aetna | 1959 |
| Mr. James David Clark | Senior VP, Controller & Chief Accounting Officer | 1965 |
| Mr. David A. Falkowski | Executive VP & Chief Compliance Officer | — |
| Mr. Samrat S. Khichi Esq. | Executive VP of Corporate Affairs & Chief Legal Officer | 1967 |
| Ms. Heidi B. Capozzi | Executive VP & Chief People Officer | 1970 |
| Mr. Gustavo A. Giraldo | Head of Markets of Healthcare Benefits | 1972 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.38
- MACD 12/26/9
- -1.09
- EMA 9 of MACD
- -0.94
- MACD histogram
- -0.16
- SMA 50
- $89.97
- Price below SMA 50
- EMA 50
- $90.28
- Price below EMA 50
- SMA 200
- $89.02
- Price above SMA 200
- EMA 200
- $87.65
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $104.00
- Average
- $108.00
- High
- $114.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.7 | +16.2 | ||||||||||
| 2022 | +2.3 | -2.5 | -0.8 | -4.9 | +0.3 | -4.0 | +1.9 | +2.2 | -4.6 | -3.1 | +7.7 | -8.3 |
| 2023 | -5.0 | -4.5 | -9.9 | -3.7 | -7.9 | +0.4 | +7.1 | -11.9 | +6.3 | -1.0 | -1.1 | +15.3 |
| 2024 | -8.0 | +0.6 | +8.0 | -14.9 | +5.8 | -1.9 | +3.7 | -4.6 | +9.6 | -8.3 | +7.2 | -24.0 |
| 2025 | +27.7 | +17.5 | +4.4 | -1.9 | -7.8 | +8.5 | -10.8 | +17.1 | +1.8 | +1.7 | +2.4 | +0.3 |
| 2026 | -7.0 | +5.9 | -12.0 | +14.9 | +10.8 | +14.2 | -0.4 | -10.9 | -12.2 | +5.9 | +1.1 |
Corporate actions
Upcoming
No upcoming corporate actions for CVS



